Announced Thu, 13 Aug · 18:12 IST
Q1 FY27 results: Revenue up 65% YoY, PAT surges over 10x to Rs 1.18 crore
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.0%1-day move
₹73.97
prior close
₹77.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
—+0.8—-0.3-1.0+3.1+4.1+5.0+8.0—————
Up moveDown movePending
AI summary
Novelix Pharmaceuticals (formerly Trimurthi) reported Q1 FY27 standalone unaudited results. Revenue from operations rose 65% YoY to Rs 3,691.39 lakhs versus Rs 2,235.12 lakhs. Net profit surged to Rs 117.89 lakhs versus Rs 10.70 lakhs. Profit before tax stood at Rs 111.53 lakhs versus Rs 16.94 lakhs. Basic EPS was Rs 0.49 versus Rs 0.09. Auditor CVS Balachandra Rao and Co issued an unqualified limited review report with no observations.
Likely market impact
Strong top-line and bottom-line growth signal improving business momentum, though small base and trading-heavy model may keep future quarters volatile.